2nd Quarter - Amendment

AMGEN, INC. for AMGEN INC

Firm
Client
Income
—
Expenses
$1,950,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report Jul 20, 2023 $1,950,000 Replaced
2nd Quarter - Amendment (this page) Jul 21, 2023 $1,950,000 Yes

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 830/ S 1375 HELP Copays Act HR 485 Protecting Health Care for All Patients Act HR 1613 to amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program HR 2534 PROTECT 340B Act of 2023 HR 3561 the PATIENT Act S. 1542 DRUG Act S. 1967 PBM Act Issues related to cardiovascular disease awareness and treatment Issues related to Federal Trade Commission FDA issues Issues related to clinical trial diversity Issues related to patient affordability issues, including copay cards, copay accumulators, copay maximizers, National Benefit Payment Parameters Biosimilars reimbursement issues, no specific bill Supply Chain Issues, no specific bill Issues related to 340B Issues related to pharmacy benefit managers

LobbyistCovered position, as disclosed
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
JORDAN LYNN LAYSON —
KIMBERLY LOVE —
WINTA MENGHIS —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS)

Bills named: H.R. 3561 (118th), S. 127 (118th), H.R. 830 (118th), S. 113 (118th), H.R. 2534 (118th), S. 1542 (118th), H.R. 1613 (118th), S. 1967 (118th), H.R. 485 (118th)

Medicare/Medicaid MMM

Issues related to drug pricing reform -Changes to Public law 117-1769 Inflation Reduction Act -Awareness of implications to patients and research and development of Public law 117-1769 Inflation Reduction Act S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Manager Transparency Act HR 485 Protecting Health Care for All Patients Act HR 1613 To amend title XIX of the Social Security Act to improve transparency and prevent the use of abusive spread pricing and related practices in the Medicaid program HR 2534 PROTECT 340B act of 2023 HR 3561 the PATIENT act Issues related to cardiovascular disease awareness and treatment Issues related to ESRD Issues related to asthma and self-administered drug list Issues related to reimbursement for biologics/biosimilars

LobbyistCovered position, as disclosed
L NICOLE CURRIE —
RUTH HOFFMAN —
JESSE KERNS —
JORDAN LYNN LAYSON —
KIMBERLY LOVE —
WINTA MENGHIS —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Bills named: S. 127 (118th), H.R. 485 (118th), H.R. 1613 (118th), H.R. 2534 (118th), H.R. 3561 (118th), S. 113 (118th)

Taxation/Internal Revenue Code TAX

Issues related to corporate and international tax, including regarding Public Law 115-97, Tax Cuts and Jobs Act Issues related to Puerto Rico Issues related to OECD negotiations on the taxation of global income HR 3938 Build it in America Act

LobbyistCovered position, as disclosed
L NICOLE CURRIE —
JORDAN LYNN LAYSON —
KIMBERLY LOVE —
HOWARD MOON —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3938 (118th)

Copyright/Patent/Trademark CPT

S. 79 Interagency Patent Coordination and Improvement Act of 2023 S. 113 Prescription Pricing for the People Act of 2023 S.127 Pharmacy Benefit Transparency Act S. 150 Affordable Prescriptions for Patients Act of 2023 S. 148 Stop STALLING Act S. 142 Preserve Access to Affordable Generics and Biosimilars Federal Trade Commission related issues, no specific bill Issues related to the Patent Act, no specific bill Issues related to March-In/Bayh Dole, WTO/TRIPS waiver, no specific bill Issues related to False Claims Act Issues related to FDA/PTO coordination Issues related to patent thickets/product hopping

LobbyistCovered position, as disclosed
L NICOLE CURRIE —
JESSE KERNS —
JORDAN LYNN LAYSON —
KIMBERLY LOVE —
HOWARD MOON —
WILLIAM O'BRIEN —
GREGORY PORTNER —
HELEN RHEE —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 148 (118th), S. 127 (118th), S. 142 (118th), S. 150 (118th), S. 79 (118th), S. 113 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.